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Risk Models for Breast Cancer and Their
Validation
Adam R. Brentnall and Jack Cuzick
Abstract. Strategies to prevent cancer and diagnose it early when it is most
treatable are needed to reduce the public health burden from rising disease
incidence. Risk assessment is playing an increasingly important role in tar-
geting individuals in need of such interventions. For breast cancer many in-
dividual risk factors have been well understood for a long time, but the de-
velopment of a fully comprehensive risk model has not been straightforward,
in part because there have been limited data where joint effects of an exten-
sive set of risk factors may be estimated with precision. In this article we
first review the approach taken to develop the IBIS (Tyrer–Cuzick) model,
and describe recent updates. We then review and develop methods to assess
calibration of models such as this one, where the risk of disease allowing
for competing mortality over a long follow-up time or lifetime is estimated.
The breast cancer risk model model and calibration assessment methods are
demonstrated using a cohort of 132,139 women attending mammography
screening in the State of Washington, USA.
Key words and phrases: Breast cancer, calibration, risk assessment, breast
density, Tyrer–Cuzick model, IBIS model.
1. INTRODUCTION
Unlike lung cancer (tobacco smoking) and cervix can-
cer (persistent infection with the human papilloma virus)
where a single factor explains the majority of the cases, a
large number of factors have been found to be important
for determining the risk of breast cancer. An increased
risk in women with a family history appears to have been
known in ancient Roman times [59], and in 1842 Rigoni-
Stern reported that nuns had an increased risk of breast
cancer [53, 26], paving the way for further research which
established that not having a child or having a first child-
birth at an older age increased the risk of this disease.
Much of the modern work on risk factors was done by
Macmahon and colleagues, mostly at Harvard [43]. Pike
and colleagues emphasized the link with oestrogens and
proposed that much of the population risk could explained
by computing the cumulative lifetime exposure to oe-
strogens based mostly on age at menarche, childbearing
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history and age at menopause [49]; an important meta-
analysis and update on these and other factors was pro-
vided by Beral and colleagues [47].
In 1976, Wolfe discovered that breast density was an-
other key risk factor that was broadly unrelated to the
known classical factors, but of roughly equal importance
in their combined predictive value [69]. This has been fur-
ther developed by Boyd [11, 10], McCormack and others
[45]. In the same paper, Wolfe also suggested [69] using
breast density for risk assessment to determine how best
to use mammography for breast cancer screening. Several
decades later, advances in the ability to accurately strat-
ify women into higher and lower-risk groups are likely
to move early detection strategies towards this vision,
and replace ‘one-size-fits-all’ screening with so-called
‘risk-adapted’ programs in which both the frequency with
which a woman is screened and the modality are chosen
based on the risk of breast cancer. Motivations include
the identification of women at extremely high risk, who
are potential candidates for risk-reducing surgery or pre-
ventive therapy [29], delineation of a group at moderately
enhanced risk who might benefit from enhanced screen-
ing [60], and identification of populations at sufficiently
low risk so as to require less frequency or even no screen-
ing.
A number of risk models have been developed, mostly
for Caucasian women living in North America and West-
ern Europe [32, 18, 4]. In this article, we focus on risk
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assessment using the Tyrer–Cuzick model [63]. This is a
hybrid of two popular sub-models often used for breast
cancer risk assessment: a genetic segregation model for
familial risk that is combined with a proportional-hazards
regression model for other risk factors.
Breast cancer risk factors in the model broadly fit into
five general categories: (1) family history and highly pen-
etrant dominant genetic mutations; (2) factors associated
with oestrogen exposure, including age at first childbirth,
age at menopause and menarche (beginning of periods),
use of hormone replacement therapy, height and weight;
(3) certain types of prior benign breast disease, (4) breast
imaging features seen on the mammogram—notably the
amount of dense tissue (opaque areas on a mammogram
or breast x-ray); and (5) common but individually less
penetrant genetic differences (single nucleotide polymor-
phisms, SNPs), where several hundred relatively common
genetic variants that individually have a small impact on
disease have been identified, and that jointly make an im-
portant contribution to overall risk assessment via a ‘poly-
genic risk score’ [44]. There are also some other apparent
risk factors which are harder to quantify, but which may
improve the performance of the model.
In the rest of this paper, we outline the statistical ba-
sis of our model, review and develop methods to as-
sess model calibration that include competing mortality
(which has been handled differently in different papers),
and apply our model and calibration assessment methods
to data from a large cohort of women attending mammo-
graphic screening in the State of Washington, USA.
2. BREAST CANCER RISK ASSESSMENT
2.1 Background
To provide an assessment of the risk of disease occur-
ring within a person’s residual lifetime it is important
to take into account competing risks that could lead to
death from other causes. In a classical ‘latent lifetimes’
framework [20] each individual is subject to m potential
causes of death with times Tj (j = 1, . . . ,m) and we ob-
serve their actual time of death T˜ = min(T1, . . . , Tm) and
the specific cause J = 1, . . . ,m. This framework assumes
that each death is attributable to a single cause, or a de-
fined group of causes. We extend this approach to also
include the incidence of breast cancer, which is our princi-
ple interest, and do not consider death after breast cancer
occurs.
Multiple modes of failure are conveniently charac-
terised using functions for the rate at which each cause
J occurs at each follow-up time, given that the person
has not yet died, or experienced a specific event of in-
terest. More precisely, this cause-specific hazard for j =
1, . . . ,m is defined as
(1) hj (t) = lim
→0
P(Tj < t +  | T˜ ≥ t)

.
Equation (1) is estimable due to conditioning on (T˜ ≥ t).
Another measure of risk that is sometimes considered is
the proportion of the population who have event J when
followed up to time t . This cumulative incidence function
is defined by
(2) P(J = j, T˜ ≤ t) =
∫ t
0
hj (u)S(u)du,
where
S(t) = P(T˜ > t)
= exp
{
−
∫ t
0
m∑
k=1
hk(u)du
}
is the marginal (all-cause) survivor function for T˜ . When
there is just one cause (death, say) then (2) is the cumula-
tive distribution function (for time of death).
Breast cancer risk models within this framework typi-
cally consider two causes (m = 2): T1, the time to diagno-
sis of breast cancer and T2, the time to death from other
causes (excluding breast cancer mortality, which can’t oc-
cur before the time of diagnosis), so that T˜ = min(T1, T2).
Risk assessment for a women usually takes place when
current age t0 > 20 years, and the aim is to assess the ab-
solute risk of breast cancer between age t0 to age t , con-
ditional on q risk factors x = (x1, . . . , xq). This may be
done by extending (2) to condition on risk factors x and
age at risk assessment t0 through
P(J = 1, T˜ ≤ t | x, T˜ > t0)
=
∫ t
t0
h1(u | x) exp
[
−
∫ u
t0
{
h1(v | x)
(3)
+ h2(v | x)}dv
]
du
≡ Px(t0, t),
where h1(t | x) is the conditional hazard of breast cancer
at age t (cf. equation 1) and h2(t | x) is the conditional
hazard for competing mortality. In practice, and following
[32], competing mortality has often been taken to depend
only on age and has been calibrated using national mor-
tality statistics excluding breast cancer. This is reasonable
for breast cancer, as it is not strongly linked other causes
of death, but is more problematic, for example, for lung
cancer, where tobacco smoking is a major factor for it and
other causes of death such as cardiovascular disease.
Breast cancer specific hazards have been estimated in
two ways:
1. Regression models. Risk is frequently calculated by
combination of a regression model derived from case-
control or cohort studies of specific relative risks com-
bined with absolute population-based incidence rates
from cancer registries. An early and widely used exam-
ple of this is the Gail model [32], which has been further
developed in the Breast Cancer Surveillance Consortium
(BCSC) model [16, 61, 46].
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2. Estimation from family pedigree data of the proba-
bility of carrying one or more high-risk mutations using
segregation analysis, and then using the penetrance of a
mutation to alter age-specific risk [18]. Two examples are
BRCAPRO and BOADICEA [48, 4].
A novel aspect of the Tyrer–Cuzick model is that it em-
ploys both methods [63]. The segregation model estimates
the hazard function hG(t | x1) at age t due to genetic
factors, conditional on information (denoted x1) about
a woman’s family history (family tree) of breast and/or
ovarian cancer, and results of any tests in the family from
known highly penetrant breast cancer genes BRCA1 and
BRCA2. This is then combined with a relative hazard re-
gression function r(x2) > 0 based on other risk factors
(x2) through
(4) h1(t | x1,x2) = hG(t | x1)r(x2).
We divide family history into two factors x1 = {x(a)1 ,x(b)1 }
corresponding to (a) breast and (b) ovarian cancer. The
vector x(·)1 has components for event time, censoring in-
formation and family relationships, and x2 is based on the
other risk factors shown in Table 1. Risk models that only
account for family history based on a segregation model
do not use x2. Regression-only models developed are of-
ten proportional-hazards models of the same form as (4),
but with age-specific population rates instead of hG(·);
partial information on family history of breast cancer can
be included in the regression function, for example, by in-
TABLE 1
Summary of risk factor parameters in model
Category Hazard ratio Mean risk Reference category
(a) Classic risk factors
Menopause age (y) per 5y 1.14 1.08 45–49y
Menarche age (y) <11 1.16 1 13y
11 1.07
12 1.07
13 1
14 0.98
15 0.93
16 0.88
17 or older 0.81
Height (m) <1.6 1 1.1 <1.6 m
1.6–1.7 1.05 + 2 ∗ (height − 1.6)
1.7 or taller 1.24
Body mass index <21 1 1.24 <21
(kg/m2) 21 to <23 1.14
(post-menopausal only) 23 to <25 1.15
25 to <27 1.26
27 or more 1.32
Age at 1st Nulliparous 1 1 Nulliparous
childbirth (y) <17–19 0.74
20–24 0.77
25–29 0.87
30–34 1.01
35+ 1.11
Menopausal Not current 1 1 Not current
hormone therapy Estrogen-only (current) 1.4
Combined (current) 2
Benign disease Nonproliferative/none 1 1 None
Proliferative (usual type) 2
Atypical hyperplasia 4
Lobular carcinoma in situ 8
(b) New in v8
Breast density residual Visual asssessment scale 1.4 per SD 1 Average density
(age 40y+) BI-RADS density 1.4 per SD (age and BMI
Volumetric percentage 1.4 per SD adjusted)
SNPs Continuous Input 1 Average woman
SD, standard deviation; SNP, single nucleotide polymorphism risk score.
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cluding a covariate for the number of affected first-degree
relatives.
2.2 Tyrer–Cuzick Segregation Model
2.2.1 Statistical model. The genetic risk of breast can-
cer is modelled through estimates of mutations in BRCA1
and BRCA2 genes and an unknown dominant gene. Some
of the genes which make up the unknown component have
been discovered [28], but most have not, and are only in-
ferred. Even the known ones are rare and individually do
not make a major contribution, and are not so commonly
tested for even in women with a family history. We use
the variable c1 for BRCA1/2 status (0 if not a BRCA1/2
carrier, 1 if a BRCA1 carrier, and 2 if BRCA2 carrier; joint
carriers are extremely rare and are modelled as BRCA1
carriers). The unknown dominant gene is denoted c2 (0, 1
if respectively, not a carrier or a carrier). The model makes
the following assumptions.
A.i Breast x(a)1 and ovarian cancer x
(b)
1 family histo-
ries are conditionally independent given c1 and c2:
p(x1 | c1, c2) = p{x(a)1 | c1, c2}p{x(b)1 | c1, c2},
where p(·) is general notation to denote a probability den-
sity or mass function.
A.ii c1 and c2 are independent: {p(c1, c2) = p(c1)×
p(c2)}.
A.iii The unknown gene c2 is not associated with ovar-
ian cancer [p{x(b)1 | c1, c2} = p{x(b)1 | c1}].
A.iv The penetrance SG(t | c1), that is, the probability
of developing disease by age t , is known for breast and
ovarian cancer in BRCA1/2 carriers. The prevalence p(c1)
of BRCA1, BRCA2 and the unknown gene are known in
the population.
A.v A proportional-hazards model is assumed for the
incidence associated with the unknown gene using two
parameters θ = (β, γ ) through
(5) SG(t | c1, c2; θ) = S0(t | c1)exp(γ c2),
where γ quantifies the log relative hazard attributable to
the unknown gene, β is its prevalence (the per-allele pro-
portion is 1 − √1 − β), and S0(t | c1) is a baseline sur-
vivor function. From assumption (A.iv) and equation (5)
the baseline survivor function is obtained by solving
(6)
SG(t | c1; θ) = (1 − β)S0(t | c1)
+ βS0(t | c1)exp(γ c2),
for example, via a Newton-Raphson iteration [63].
A.vi Mendelian inheritance, that is, there is a 50%
chance that one of the two alleles from each parent is in-
herited by their offspring.
From these assumptions the breast cancer risk conditional
on x1 is obtained as
(7)
SG(t | x1; θ) =
2∑
c1=0
1∑
c2=0
SG(t | c1, c2; θ)
× p(c1, c2 | x1; θ),
where the weights p(c1, c2 | x1; θ) in (7) are obtained
from the following application of Bayes’ rule. Denoting
d = (c1, c2) then
(8) p(d | x1; θ) = p(x1 | d; θ)p(d; θ)
p(x1; θ) .
p(d; θ) uses assumptions given in (A.ii, A.iv, A.v), and
p(x1 | d; θ) is obtained following A.vi (described in more
detail in [63]), first separately for breast x(a)1 and ovar-
ian cancer x(b)1 family histories and then they are com-
bined through (A.i). When gene testing has been done for
BRCA1/2 the values for c1 are taken from this, and the fa-
milial contribution only applied to the unknown gene c2.
Most of the computer code in the Tyrer–Cuzick algorithm
is involved in calculating the likelihood p(x1 | d; θ).
2.2.2 Parameter estimates. Some changes to the seg-
regation model have been made since the original model
[63], starting from version 7 onwards. BRCA1/2 preva-
lence and penetrance are now from the 1950+ birth cohort
estimates reported in [4]. The penetrance estimate is now
lower than used in original model [63] (previously taken
from [31]), which was attributed in [4] to bias in the orig-
inal estimate [31] resulting from a focus on families with
multiple cases of breast cancer. Prevalence of BRCA1 is
taken to be 0.06% and for BRCA2 is 0.10% (previously
0.11% and 0.12%, respectively). Smoothed first breast
cancer rates from the Thames Registry 2005–2009 were
used to calibrate overall risk, based on data reported by
5y age group and smoothed by loess (with the smoother
‘span’ parameter 0.2 chosen by eye). The unknown gene
calibration has not been altered since the model was first
introduced (β = 11.4% and exp(γ ) = 13.04, fitted to data
from [3]; see [63]). The impact of the unknown gene de-
pends mostly on the product β exp(γ ) and it is difficult
to accurately estimate these two parameters separately.
The best fit gave a very large value for exp(γ ) but al-
most equally good fits would arise if γ was substantially
reduced and β increased accordingly. Attributing risk to
a single gene is a simplification, as risk is likely to re-
flect a combination of genes. However it is clear that the
contribution of this unknown gene is greater than that for
BRCA1 or BRCA2, any other known gene or combination
of single nucleotide polymorphisms, and treating this ei-
ther as a single unknown gene or a polygenic risk score
has minimal impact on its predictive value.
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2.3 Regression Model
2.3.1 Model. The relative hazard r(x2) in model (4) is
normalised by the mean risk in the population. This re-
quires information on the relative hazard associated with
other nonfamilial (personal, hormonal and lifestyle) risk
factors {denote this function φ(x2) > 0} and their popu-
lation prevalence {f (x2) where
∫
f (x2)dx2 = 1} in or-
der to obtain the normalised relative hazard
(9) r(x2) = φ(x2)∫
φ(x2)f (x2)dx2
.
In the Tyrer–Cuzick model this is approximated by treat-
ing each risk factor as independent (breast cancer risk fac-
tors in the model are largely independent of each other)
and taking
(10) r(x2) =
q∏
j=1
{
φ(x2j )∫
φ(x2j )f (x2j )dx2j
}
.
When the value of a risk factor is unknown it can be left
blank and the normalised relative hazard associated with
that factor is taken to be 1 (woman assumed to have pop-
ulation risk). The mean risk constants used in the model
are shown in Table 1.
2.3.2 Parameters. The relative hazards and prevalence
of risk factors in the original model were reported in [63],
and included in Table 1. There have been changes and the
current values are described below.
Atypical hyperplasia or LCIS The original model
treated atypical hyperplasia or lobular carcinoma insitu
(LCIS) as an independent risk factor. Evidence in [25]
and [9] indicated that other risk factors should not be in-
cluded when a women has been diagnosed with atypical
hyperplasia as it is more of an intermediate endpoint. As
a result, we modified the model to take the maximum risk
of atypical hyperplasia (only), LCIS (only) and family
history risk combined with other risk factors (based on
the 10y risk). For example, a young BRCA1/2 carrier with
atypical hyperplasia would not have her risk assessment
modified by atypical hyperplasia. This is likely to be con-
servative, but currently there is inadequate data to model
the joint effects of atypia and other risk factors accurately.
Unknown benign disease In general, the risk of subse-
quent breast cancer associated with a benign lesion de-
pends on the histology, with no increased risk associated
with nonproliferative lesions, about a two-fold risk asso-
ciated with hyperplasia of the usual type and about a 4-
fold risk associated with atypical hyperplasia [27]. Based
on prevalence data reported by [27], the relative hazard
from benign disease when a women has had a biopsy but
pathology is unknown is taken to be 1.3; this option was
not available originally. Nonbiopsied lesions are not con-
sidered in the model.
Menopause hormone therapy The model assumes a
maximum relative hazard of 2.0 for combined therapy
with an oestrogen and progestin and 1.4 for oestrogen-
only hormone therapy. The relative hazard begins at unity
in year 1, is half the maximum excess relative hazard in
year 2 and then the maximum relative hazard therafter un-
til stopping therapy. Risk is then ramped down following
cessation to be 2/3 of the maximum excess in the first
year after stopping, then one third in the next year, and
no increase thereafter. The relative risk is adjusted if BMI
(body mass index) is known, being decreased by 10% of
the average excess risk if obese (BMI ≥ 30 kg/m2), and
increased by 10% if BMI <25 kg/m2 (not overweight
or obese). These assumptions are based on results from
the Women’s Health Initiative trial [17]) and the Million
Women Study [51].
2.4 New Additions to the Model
2.4.1 Mammographic density. Breast density is corre-
lated with some of the other risk factors in the model,
most strongly age and body mass index. It is also mea-
sured in different ways that require different calibration.
We allow three different ways to input density: a visual
assessment in which (ideally) two readers estimate the
percentage of the breast covered by dense (opaque) tis-
sue and the average is used, the BI-RADS system which
corresponds to four categories, and an automated volu-
metric system (Volpara) that estimates the percentage vol-
ume of dense tissue based on the radiographic intensity of
each pixel. In order to incorporate breast density into the
model without changing the effect sizes of the other fac-
tors, we first developed a measure of breast density which
is independent from age and BMI at mammogram, by tak-
ing the difference between observed and expected density
given age and BMI. This was developed for the different
measures in case-control studies, where expected density
was modelled in controls by fitting a generalized additive
model [70] of different breast density measures against
splines for age and BMI (see Figure 1 for a fit to volu-
metric percent density). The risk associated with density
was then calibrated by estimating the effect of the density
residual, adjusted for other factors in the Tyrer–Cuzick
model using case-control and cohort studies [68, 15, 14].
2.4.2 Polygenic risk scores. Numerous studies have
demonstrated the utility of polygenic risk scores. These
use common gene variants which individually carry small
risks but as a group provide useful information. Their util-
ity has been observed in average risk women [66, 46] and
in high-risk women [22, 30], and they combine effectively
independently with classical risk factors and breast den-
sity [64, 65]. Currently, the breast cancer association con-
sortium has validated more than 170 risk-modifying SNPs
at genome-wide significance [44], and this is likely to in-
crease still further.
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FIG. 1. Volumetric percentage density vs age and body mass index (BMI), with joint nonparametric smooths (line —). Taken from [12].
To provide an overall relative risk estimate from a col-
lection of independent SNPs polygenic risk scores may
be obtained by using published data on their per-allele
risks, and allele frequencies. First, the odds ratio for each
of the three SNP genotypes is determined (no risk alleles,
1 risk allele, and 2 risk alleles) and these are normalised
to obtain an average of unity using reported risk allele fre-
quencies. In our model, we assume the odds of two copies
of the abnormal gene is the square of that for one copy,
and their distribution follows the Hardy–Weinberg law.
Finally, to obtain an overall polygenic risk score the odds
ratios for each of the genotypes are multiplied together
assuming independence [46].
Data show very small correlations between polygenic
risk scores and classical risk factors. We have observed
that an accurate fit is obtained by treating the score as in-
dependent of the other factors in the Tyrer–Cuzick model
[22, 30, 65]. However, theoretically, a polygenic risk score
will explain some of the genetic aggregation modelled
through the segregation model, and so this should be
down weighted in the risk assessment. Work to refine this
component is ongoing.
3. COMPARISON WITH OTHER RISK MODELS
It is important to understand differences between risk
models, both for use of the models and to refine the scien-
tific process of improving risk assessment. Here we note
some differences between the Tyrer–Cuzick and other
models.
3.1 Segregation Models
Some segregation models, including BRCAPRO [48],
calculate breast cancer risk only based on estimating the
likelihood of carrying major genes based on a personal
and family history of breast, ovarian or other cancers re-
lated to these genes. The main aim of such models is to es-
timate risk of being a BRCA1/2 mutation carrier. They are
mostly used for women with a strong family history in or-
der to determine eligibility for BRCA1/2 testing. They in-
corporate both pedigree information including age at on-
set and results of genetic testing for BRCA1 and BRCA2
in the women and their relatives. Such models are less
suitable for risk assessment of breast cancer in the wider
population, partly because they do not allow for other un-
known genetic factors in the model.
The BOADICEA model accounts for other rare but
highly penetrant genes (PALB2, CHEK2, ATM), and uses
a polygenic model to allow for (unobserved) risk due to
other genetic factors than those measured [42]. Define
c∗1 = 0 if not positive for one of the genes, c∗1 = 1 if test
positive for BRCA1, c∗1 = 2 if test positive for BRCA2 (but
not BRCA1), c∗1 = 3 if test positive for PALB2 (but not
BRCA1/2) and so on for next CHEK2 and last ATM. Thus,
very rare individuals who test positive for more than one
gene are assigned a group c∗1 = 0, . . . ,5 based on a hi-
erarchy. The model has the following form for the breast
cancer specific hazard:
h1
{
t | c1, u(t)}
= h1B(t) exp
{ 5∑
j=1
βj (t)I
(
c∗1 = j
)+ u(t)
}
,
where t is age, h1B(t) is a baseline hazard function, I (·)
the indicator function, βj (t) are time-dependent relative
hazards for each genotype, and u(t) is a time-dependent
random effect from a normal distribution with mean zero
and standard deviation σt . When the woman has not been
personally tested, the probability of being a carrier is es-
timated based on the pedigree and testing results (if any)
in family members. The random (polygenic) effects arise
from a combined effect of several unmeasured and largely
unknown genes, each of which contributes a small effect.
Large scale genome-wide association studies have identi-
fied that the polygenic model for genetic susceptibility is
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partly correct, but a large proportion of familial aggrega-
tion of risk is still not explained by known major genes or
polygenic risk [44].
For most pedigrees arising in the general population
one might expect only small differences for risk estimates
from polygenic vs. single unknown gene models. Qual-
itatively, the unknown single dominant gene model is a
good approximation to the polygenic model: the geno-
type is never observed and so gives rise to a range of ef-
fects through equations (7) and (8). Indeed, one study that
compared the fit between the unknown dominant gene and
polygenic models did not show an appreciable difference
between them when considering additional genetic factors
other than BRCA1/2 [5].
Another difference between BOADICEA and Tyrer–
Cuzick is that the hazard for the unknown genetic effect
γ is assumed to not vary with age in the Tyrer–Cuzick
model, whereas the polygenic variance varies with age
in the BOADICEA model. Thus, the BOADICEA model
leads to a larger decline in the relative risk as the age of
the affected relative increases and appears to fit better with
the literature. We will update this aspect of the model in
the next version.
3.2 Regression Function Models
Several models have been developed based on a regres-
sion function only. These include the Gail (or BCRAT)
[32], the Breast Cancer Surveillance Consortium (BCSC)
[61, 62] and Rosner–Colditz models [52, 72]. Neither the
Gail nor BCSC model include all the risk factors included
in the Tyrer–Cuzick model, but they do account for ethnic
differences. The Rosner–Colditz model includes the terms
for the same broad risk factors as in the Tyrer–Cuzick
model, and some additional factors including alcohol con-
sumption, adolescent body somatotype (shape/size) and
hormone levels. Assumptions on the risks and prevalence
of risk factors differ between the models, as do the use of
interaction terms.
The Tyrer–Cuzick model includes an interaction be-
tween menopausal status and BMI, assuming it is only a
postmenopausal risk factor. Some data suggest that BMI
may actually be a protective factor for premenopausal
breast cancer but this is not included in the model [58].
Interactions are also included for BMI and HRT (as dis-
cussed above), and atypical hyperplasia (or LCIS) and all
other risk factors in that it is treated as an intermediate
endpoint, and the maximum risk for it alone or all other
factors combined is used, following analysis from [9]. No
other interaction terms are currently included.
The Gail model includes an interaction between (i) eth-
nicity and all other risk factors, and for certain ethnic
groups an interaction between (ii) age and number of
biopsies, and (iii) age at first child and number of affected
first-degree relatives (negative interaction). For example,
both latter interactions are included for white women, but
they are not used for Asian women.
The BCSC model includes interactions between a
woman’s age with (i) ethnicity, (ii) benign disease,
(iii) family history (negative interaction) and (iv) breast
density (negative interaction), by allowing for different
regression coefficients in 10y intervals starting at age 40y
[62].
The Rosner–Colditz model allows for interactions be-
tween: (i) BMI and duration of premenopausal period
(time from menarche to start of menopause) (ii) BMI and
current duration of menopausal interval, (ii) alcohol after
menopause and hormone replacement therapy, (iii) benign
disease with age at menarche, (iv) benign disease with du-
ration of premenopause, (v) benign disease with duration
of menopause, (vi) height with duration of premenopause
(vii) height with duration of postmenopause.
All the models (except Tyrer–Cuzick) include interac-
tions relating to benign disease, but their forms are quite
different. In the Gail model, for white women the rela-
tive risk of previous biopsies is less in women older than
50y than for younger women. In the BCSC cohort used
to fit their model [62] this pattern was not observed for
proliferative disease, and for nonproliferative disease the
direction was even reversed (a larger effect for women
older than 50y). In the Rosner–Colditz model, there is
a positive interaction with age at menarche and a neg-
ative interaction for the other terms [52], suggesting an
older age at menarche is not protective for women with
benign disease. These three models have been fitted in
populations with individual-level data. Relative hazards
for white women in the Gail model were estimated us-
ing a case-control study with 2842 cases and 3146 con-
trols, including 179 cases with a prior biopsy aged <50y
and 487 cases with a prior biopsy aged 50y+ [32]. The
BCSC model was fitted to a cohort with more than 1 mil-
lion women with up to 10y follow up, and included 6204
women with proliferative disease without atypia and 177
subsequent cancers [62]. A recent Rosner–Colditz model
update included approximately 100,000 women of whom
5246 had developed breast cancer. Benign breast disease
(nonproliferative and proliferative) was reported in ap-
proximately 18,000 women at entry [52].
Potential interactions between benign disease and other
risk factors have also been investigated in other stud-
ies, but also with inconclusive findings. For example, in
a cohort from Nashville a negative interaction between
nonproliferative disease and age was observed, such that
women diagnosed with nonproliferative disease at an
older age had lower breast cancer risks than women in
the cohort without proliferative disease [27]; this has not
been evaluated in any of the four models considered here.
Overall, due to the current lack of strong evidence to
support an interaction of benign disease with age, no such
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interaction is included in the Tyrer–Cuzick model, and it
assumes nonproliferative benign disease does not confer
any increased risk.
4. ABSOLUTE CUMULATIVE RISK ASSESSMENT
AND CALIBRATION
4.1 Framework
It is important to be aware of the difference between us-
ing a model to project risks and calibrating a model from a
cohort where follow-up data already exists. In the former
case routine data only provides risk assuming no inter-
current mortality, and a specific adjustment needs to be
made for competing mortality (cf. equation (3)). In the lat-
ter case, inter-current deaths are known and can be treated
as part of the censoring process. This has led to different
methods for computing absolute cumulative risk, which
are essential for interpreting the model predictions, and
subsequently to assess how well the model is calibrated to
the population under study. This has not been widely ap-
preciated, and can lead to different estimated values of ex-
pected absolute risk from the same disease model. In this
section, we review some different methods for computing
expected cumulative risk under the following setup.
Assume there is a sample of i = 1, . . . , n independent
individuals with data on risk factors. The risk model eval-
uates each risk from current age t0 to age t , defined
as Pxi (t0i , t) or Pi(t) using shorthand notation follow-
ing equation (3). The time to breast cancer or death is
subjected to right-censoring, so that one observes T˘ =
min(T1, T2, TC), where T1 is time to disease, T2 is the time
to death from other causes and TC is a right-censoring
time.
An issue to contend with for computing the expected
probability of breast cancer is that the ‘at-risk’ interval
should be from t0 to TC , whereas T˘ is often used. TC
is not observed when min(T1, T2) < TC and this presents
difficulties as its (conditional) distribution can be hard to
determine. Calculating the expected risk using probability
of breast cancer over (t0, T˘ ) is liable to underestimate ex-
pected risk. A solution is to use lifetable methods which
are based on the sub-hazard of breast cancer and not the
probability of breast cancer, but only need to be computed
over (t0, T˘ ). We next consider these different methods in
more detail.
4.2 Expected Risk Based on the Cumulative
Disease-Specific Hazard Function
The expected number of breast cancer cases in the
cohort may be obtained by first integrating breast can-
cer specific hazards over the observed follow-up period,
to obtain each individual’s cumulative hazard for breast
cancer during the period she is at risk. Formally, let
Yi(t) = I (T˘i > t) denote the at-risk process for individual
i = 1, . . . , n, and h1(t | xi ) = h1i (t) the disease-specific
hazard function sub-model. Then the expected number of
individuals with disease (J = 1) is
E(H) =
n∑
i=1
∫ ∞
t0i
h1i (u)Yi(u)du
(11)
=
n∑
i=1
H1i (T˘i),
where
H1i (t) =
∫ t
t0i
h1i (u)du.
Equation (11) may be adapted to compute the expected
number of deaths from other causes by replacing h1 with
h2, etc. Indeed, by letting h2 reflect all-cause mortality
(including breast cancers) this is equivalent to the time
honoured lifetable method to compute the expected num-
ber of deaths [40]. Thus, while it might seem surprising
to base the expected number of women diagnosed with
breast cancer on the disease-specific cumulative hazard
rather than the smaller estimate of the probability of breast
cancer, this method is firmly established in lifetable and
other settings (see, e.g., the log-rank test).
4.3 Expected Risk Based on Cumulative Incidence
The previous section is the preferred method (see be-
low) but another approach is to calculate expected risk
using the model probability of disease allowing for death
from other causes (cumulative incidence). This is most
straightforward when the model is used in a cohort with
no censoring from starting age t0 up to age t . In this case,
the expected number is a summation of the conditional
cumulative incidence in (3):
(12) E(P)(t) =
n∑
i=1
Pi(t),
where Pi(t) ≡ Px(t0, t) for the ith individual. It is ex-
tremely uncommon to have such a dataset, and the cal-
culation is more complicated under the most common
scenario of right censoring because we need an esti-
mate of P{J = 1,min(T1, T2, TC) ≤ t | xi}, whereas Pi(t)
estimates P{J = 1,min(T1, T2) ≤ t | xi} (see equation
(3)). We consider three types of censoring processes for
prospective risk calculation.
First, if censoring is fixed to be to a common follow-up
time for each patient ti = t0i + A, such as A = 5 years,
then
(13) E(P)(A) =
n∑
i=1
Pi(ti0 + A).
Second, when the censoring time TC is variable between
individuals but it is deterministic, such as being due to
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variable calendar time enrolment and a common follow-
up for all i then
(14) E(P) =
n∑
i=1
Pi(ti0 + TCi).
A third case is when the potential censoring time is un-
known but is a stochastic process with known distribution.
Then one possibility is to base expected risk on
PC(t)
=
∫ t0+t
t0
h1(u | x)
(15)
× exp
[
−
∫ t0+u
t0
{
h1(v | x)
+ h2(v | x)}dv
]
SC(u | x)du,
where SC is the survivor function for the censoring distri-
bution. Then
(16) E(P) =
n∑
i=1
PCi(ti0 + T˘i).
If SC is unknown then one will need to estimate it, for ex-
ample by assuming censoring is independent of risk fac-
tors x and using the Kaplan–Meier estimator [41].
4.4 Calibration
The above methods based on cumulative disease-
specific hazards or cumulative incidence may be used to
assess calibration by comparison of the observed number
of women with disease (O) with expected (E), both over-
all and in sub-groups [38]. If it is assumed that disease is
rare (this assumption is relaxed in Section 4.7), then a test
may be constructed assuming that O is generated from a
Poisson distribution, whose rate would be E if the model
was perfectly calibrated. Exact Poisson confidence inter-
vals on O may be used to compute a confidence interval
for O/E (treating E as fixed) and determine if it covers
unity [33].
4.5 Some Biased Estimates of Absolute Risk and
Their Effect on Calibration
Some commonly-used methods are biased, but this can
be overcome using hazard-based methods where the ap-
propriate ‘at-risk’ interval is used. We next consider three
methods that yield biased estimates of E, the expected
number of cancers, which in turn leads to biased estimates
of the observed to expected ratio O/E.
1. Under right censoring some studies [19, 24, 7, 55]
have used cumulative incidence as the measure of ex-
pected risk, but estimated it via
(17)
n∑
i=1
Pi(T˘i).
This measure of expected risk is biased towards zero be-
cause it only computes risk until the event time T˘ . For
example, suppose we wish to compute the expected num-
ber of deaths in a sample of babies over the next 200y. If
the mortality model is well calibrated but risk of death un-
til the age at which each person actually dies is summated
(as equation (17)), then fewer deaths will be expected than
the number of babies in the sample. The correct analy-
sis based on cumulative incidence would summate risk of
death by age 200y for each individual (cf. equation (12)).
In mitigation, the bias will be small, and will have a min-
imal impact on the conclusions drawn when the event is
rare.
2. In some studies it has been reported [2] that the ex-
pected number with disease is computed as
(18)
n∑
i=1
[
1 − exp{−H1i (T˘i)}],
that is, summating 1 minus the net survival (the estimand
for Kaplan–Meier estimation) rather than (11). In gen-
eral, this is biased towards zero for the expected number
of breast cancers because the term in the summation is
less than or equal to the cumulative hazard H1i (T˘i). How-
ever, this is a small bias if the cumulative hazard H is
small since 1 − exp(−H) = H + O(H 2). Also note that
1 − exp{−H1i (T˘i)} ≥ Pi(T˘i), so is less biased than sum-
mating Pi(T˘i) (i.e., equation (17)).
3. Finally, calibration of breast cancer risk has some-
times been assessed using a fixed follow-up time for all
by only including those who could be followed up at least
that long [61, 54]. This in inefficient because some data
would be excluded, and it should be used with caution
when there is censoring. For example, suppose we seek to
assess calibration of 5y risk when there is right censoring
in the data, and include only those without breast cancer
who were not censored by 5y and all breast cancer cases
diagnosed up to 5y. If the model is correct (and censor-
ing is noninformative), then O/E based on (12) will be
biased. E will be too small relative to O because some of
the noncases will have been excluded from expected risk
due to censoring, but they should have contributed to E
as they would have been counted as cases if disease had
occurred in them.
4.6 An Unbiased Estimate of Expected Risk
To avoid bias, we recommend using E(H) to obtain the
expected number with disease. This is based on the cu-
mulative hazard rather than probability of disease (cumu-
lative incidence) and has several advantages compared to
E(P) when censoring has been handled appropriately as
described in Section 4.3.
First, comparing E(H) with O is a test of whether
the disease-specific hazard model is correct. The same
method may also be used to test the competing-mortality
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model. Comparing E(P) with O is a test of whether the
model for cumulative incidence based on combining the
disease risk and competing mortality is correct, that is,
whether the marginal risk based on (3) is well calibrated.
This might require accurate knowledge and data on the
competing risk process, which is often not available. It
is uncommon for the competing mortality model to be as
well developed as the disease risk model, which is of pri-
mary interest to the epidemiologist. If the competing mor-
tality model is incorrect, but the disease model is correct,
then the expected risk will be incorrect due to an inade-
quate model for competing mortality. Conversely, even if
the cumulative incidence function risk is well calibrated,
it is possible that the competing mortality and disease
model are both wrong in different ways, and just hap-
pen to cancel each other out. Comparing the hazard sub-
models separately would identify such issues.
Second, when there is stochastic censoring equation
(11) is easier to apply than (16) because it does not re-
quire an assumption or estimate for the conditional cen-
soring distribution.
Third, it can be a more powerful test. For example, in
an extreme example of 200y follow-up on mortality in ba-
bies, then one would not be able to show that a model that
assigns a constant and excessively high mortality rate was
incorrect; whereas analysis based on summating the cu-
mulative hazard of that model to the time of each death
would yield an expected number of deaths in excess of
observed.
4.7 Extensions
We end this section by describing methods to assess
calibration not only for the total population, but also in
subgroups. For example, when the data are split into ten
groups by decile of the predicted risk at baseline then
a test of calibration (more generally model fit) across
the groups would be akin to the Hosmer-Lemeshow test
for binary outcomes [36, 38]. To extend this strategy to
the cumulative incidence framework, we construct k =
1, . . . ,K distinct groups, and assess whether the observed
risk matches expected in each of the groups. Then, the test
statistic
χ2K−1 =
K∑
k=1
(Ok −Ek)2
Ek
,
where the expected Ek are obtained as above, will be ap-
proximately χ2 with K − 1 degrees of freedom under the
null hypothesis of correct prediction and calibration.
This hypothesis testing approach has limitations.
First, power to reject inaccurate calibration is limited by
the large number of degrees of freedom. Second, with
a large enough sample size we would expect to reject
model calibration because all models are wrong, and the
approach does not directly indicate where the inaccura-
cies lie.
An alternative approach is to view testing calibration as
special case of Poisson regression. Let Oi denote whether
individual i = 1, . . . , n in the sample has disease, and Ei
be the expected risk based on the model. Then consider a
Poisson regression for
E(Oi | Ei) = exp{γ0 + γ1 log(Ei)}
= θEγ1i ,
where θ = exp(γ0) and γ1 are unknown parameters.
Setting γ1 = 1 then the maximum likelihood estimate
θˆ =∑i Oi/∑i E provides an overall ‘calibration-in-the-
large’ parameter for the entire cohort [21]. When γ1 is
also estimated then it can be used to test for calibration
across the range of expected risk (on 1 df), as well as
yielding an estimate of how closely the regression line
matches observed (γ1 = 1 being ideal; 0 being not at all).
Finally, we consider when the disease is relatively com-
mon, perhaps because focus is on a high risk group with
long follow up. In this case, the Poisson distribution no
longer approximates a binomial distribution. However,
Poisson regression may be valid if time is broken into
shorter segments where the rare disease assumption holds,
for example by year, with each segment treated as a ‘new’
observation in the Poisson regression analysis. This ap-
proach is also useful when assessing time-dependent cal-
ibration, and which we proceed to consider next.
5. TIME-DEPENDENT CALIBRATION
The focus of many studies has been on whether the
cumulative number with disease over a single follow-up
period matches the expected number. While important, it
does not assess differences through time, such as nonpro-
portionality of the observed to expected risk. In this sec-
tion, we consider techniques to assess calibration across
follow-up time, and develop new graphical methods.
5.1 Methods
One approach is simply to look at the observed and
expected number of events Nj(t) for each cause j as a
counting process. The observed number is
(19) Nˆj (t) =
∑
T˘i≤t
I (Ji = j).
The expected number, based on the cumulative hazard ap-
proach (as Section 4.2), is
Nj(t) =
n∑
i=1
∫ t
0
Yi(u)hji(u)du
(20)
= ∑
T˘i≤t
Hji(T˘i)+
∑
T˘i>t
Hji(t),
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so that we have extended (11) to be a function of t .
One may compare observed Nˆj (t) vs. expected from (20)
through follow-up time t , such as is sometimes done to
check proportional hazards [6, 34]. Cumulative pointwise
(such as from entry to time t), or interval (such as number
in a year) confidence intervals may be constructed using
exact Poisson confidence intervals, or used to undertake
hypothesis tests of calibration up to or near time t .
An issue with the comparisons based on N(t) is that
they depend on the sample size and censoring distribu-
tion, so cannot be readily used to compare between stud-
ies. To circumvent this, one might consider the comparing
the mean cumulative hazard among those at risk, that is,
for t < maxi (T˘i) comparing
(21) Hˆj (t) =
∑
T˘i≤t
I (Ji = j)
Y+(T˘i)
with its expected value
(22) Hj(t) =
n∑
i=1
∫ t
0
Yi(u)hji(u)
Y+(u)
du,
where the total number at risk at time t is Y+(t) =∑n
i=1 Yi(t). Note that equation (21) is the Nelson–Aalen
estimator of the cumulative hazard [41]. Equation (22) is
the expected cumulative hazard based on the breast cancer
risk model and observed at-risk process. Time-dependent
assessment of the observed to expected risk can be based
on Hˆj (t) vs. Hj(t) across follow-up time t . Here we treat
Hj(t) as fixed and use the usual confidence intervals for
the Nelson–Aalan estimator Hˆj (t) at different times, from
which the hypothesis of calibration at a particular time t
can also be assessed.
Other functionals of Hˆj (t) and Hj(t) might also be
used for assessment of calibration across time. Arguably
the most common functional used in applications is the
‘net’ risk
S(t) = 1 − exp{−H(t)},
which is often estimated as 1 minus the Kaplan–Meier
estimator [41]. There are two options for calculating the
expected risk. The first is a mean from the entire cohort at
baseline
(23) S(A)j (t) = n−1
n∑
i=1
[
1 − exp{−Hji(t)}].
The second is to use the mean hazard in those still at risk
at time t through
(24) S(B)j (t) = 1 − exp
{−Hj(t)}
and (22).
A disadvantage of the cumulative hazard (22) and net
risk (23), (24) is that interpretation of the component
terms is not straightforward in relation to the observable
risk in equation (2). However, if we weight (21) by the
proportion at risk using the Kaplan–Meier estimator Sˆ(t)
for all-cause survival (i.e., the survival endpoint is disease
or death), then we recover an estimator of the cumulative
incidence function through
(25) Fˆj (t) =
∑
T˘i≤t
I (Ji = j)
Y+(T˘i)
Sˆ(T˘i),
and inference may be based on estimates of its variance
[41]. Expected risk may be obtained from
(26) F (A)j (t) = n−1
n∑
i=1
Pi(t),
or the mean expected risk at each t over the n individuals.
5.2 Summary
Our recommendation is to focus on comparisons only
involving the disease-specific hazard to assess O vs E
through follow-up time t . For exploratory plots, we pre-
fer use of the cumulative hazard comparison of (22) with
(21). There are several reasons for these recommenda-
tions.
First, as for overall calibration, the method may be used
to assess the disease risk and competing mortality sub-
models separately. The cumulative hazard analysis ex-
tends quite naturally a total number of events comparison,
but avoids dependence on the censoring distribution.
Second, focusing on the hazard leads to using the ob-
served at-risk process to calculate expected risk, which
appears to be a more robust method to assess model cal-
ibration than only using a risk assessment estimate on
everyone at baseline. For instance, if those censored or
lost to follow-up are more likely to be at higher predicted
risk at entry, then estimates of their expected risk will dif-
fer, and so comparison of expected risk between methods
based on using the at-risk-process or everyone at baseline
is a way to assess whether the censoring process was as-
sociated with predicted risk. In general terms this issue
has parallels with relative survival, where one might con-
sider the Ederer-I approach (mean risk) or the Ederer-II
approach (use the at-risk process) [56].
Third, a statistical advantage of the cumulative hazard
compared to the cumulative incidence function is that it
may have a smaller variance because it does not require an
assumption or estimation of all-cause survival (equation
(25)).
Finally, in the exploratory plots when the aim is to as-
sess calibration of a risk model, then differences between
the observed to expected cumulative hazard seem easier to
interpret than the other methods. In contrast, the cumula-
tive incidence function weighs the cumulative hazard by
all-cause survival. The component terms have a natural
interpretation, but the observed to expected comparison
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is perhaps less easy to interpret for assessing calibration
than cumulative cause-specific hazards, because changes
could be due to either lack of calibration in the disease
or competing mortality models. Kaplan–Meier estimation
transforms the cumulative hazard through 1 − exp(−H),
so that differences between large cumulative hazards are
downweighted. This makes changes in the calibration plot
with time less easy to relate to calibration at the hazard
level. For example, it is easier to assess whether the hazard
function is constant through time by plotting the Nelson–
Aalan estimate of the cumulative hazard, than by plotting
1 minus the Kaplan–Meier estimator.
6. EXAMPLE
6.1 Data
We have previously reported an evaluation using the
Tyrer–Cuzick model in a cohort from the State of Wash-
ington, USA [14]. Between 1996 and 2013, 132,139
women aged 40–73y completed a risk questionnaire and
had a measure of breast density taken at entry. They were
followed up beginning 6-months after the entry mammo-
gram to the earliest of diagnosis of invasive breast can-
cer or censoring. Women were censored due to disenroll-
ment (n = 62,331, 48.2%), end of follow-up (n = 48,317,
37.3%), age 75y (n = 15,827, 12.2%), death from other
causes (n = 2328, 1.8%) or ductal carcinoma in situ (n =
637, 0.5%). Only aggregate data on competing risk causes
were made available for analysis, so we were unable to
apply methods that require individual-level data about the
cause of censoring.
6.2 Calibration
A total of 2699 breast cancers were observed (O), and
based on our preferred method (equation 11) 2757 were
expected (E), yielding O/E 0.98 (95%CI 0.94–1.02). We
next consider application of incorrect methods discussed
in Section 4.5.
A first biased assessment is cumulative incidence over
a 5y fixed-time horizon by using all the cases that were di-
agnosed in the 5y period and all noncases at risk for 5y or
more. It we calculate the expected 5y risk in those who are
at risk at 5y then E = 877 against an observed O = 1157
(O/E = 1.32). A second biased method is to summate ex-
pected cumulative incidence to the last follow-up for each
individual (equation 17), yielding E = 2605 and O/E =
1.04 (95%CI 1.00–1.08). A third biased method is to fol-
low equation (18) and summate the absolute net risks,
which gives expected number E = 2679 (O/E = 1.00).
It also instructive to repeat the above methods in a high-
risk group (> 8% ten-year net risk) where greater differ-
ences between the methods to calculate E will occur. The
Tyrer–Cuzick model with mammographic density iden-
tified 4645 women to be in this group, and 273 breast
cancers were subsequently diagnosed. Based on the pre-
ferred method (11) we find E = 349, so that O/E = 0.78
(95%CI 0.69–0.88), indicating that the model over pre-
dicted the high risk group. If instead (18) was used then
E = 324 and O/E = 0.84 (95%CI 0.75–0.95). Based on
(17) we find E = 310 so that O/E = 0.88 (95%CI 0.78–
1.00), where the 95%CI covers unity. Thus, the correct
analysis showed a lack of calibration that would not be
seen so clearly with the biased methods.
This analysis shows the method to calculate expected
risk can cause practically important differences in inter-
pretation of risk model calibration, particularly for high-
risk groups.
6.3 Time-Dependent Calibration Plots
Time-dependent calibration was assessed using the
methods in Section 5. We present results from overall
model calibration (Figure 2) and in the highest and low-
est risk deciles (Supplementary Figures S1 and S2 [13])
following [14].
Overall the model appeared well calibrated throughout
follow-up time. As follow-up started at six months, the
expected hazard in the first year was much lower than
the second year of followup. Figure 2(a) shows the model
did not adequately take into account the effect of removal
of a pool of cancers diagnosed at entry. However, sub-
sequently the model tracked the observed number quite
closely. Figures 2(c), (d) show respectively, the Nelson–
Aalan and Kaplan–Meier curves. The corresponding ob-
served to expected plots in Figures 2(e), (f) are virtually
identical using the expected risk based on those still at
risk. There is also very little difference between the two
methods to obtain expected risk using the Kaplan–Meier
approach, which indirectly confirms that censoring was
unrelated to risk assessment.
The same plots were used to assess high and low risk
groups. Supplementary Figure S1 considers women who
were in the highest predicted risk decile at entry. As noted
in Section 6.2, there is some evidence of over-estimation
from the model for this group. However, the observed to
expected plots in Supplementary Figure S1(e), (f) show
a fairly constant pattern across time, with no discernible
difference between Nelson–Aalan or Kaplan–Meier com-
parisons. Supplementary Figure S2 shows calibration of
the bottom decile, where calibration appears reasonable
through follow up time, albeit with a suggestion that the
model had a tendency to under estimate risks.
6.4 Regression Analysis
The above analysis suggests that the risk model was cal-
ibrated overall in the cohort, but tended to overestimate
risk in those predicted at highest risk; it over-estimated
risk in the first year due to omitting screen-detected cases,
but the risk predictions thereafter were stable with greater
follow-up time. All these aspects may be jointly tested
through a Poisson regression model. The model was fit-
ted with an exponential link function. The log hazard per
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FIG. 2. Overall calibration of the breast cancer risk model. (a) Observed (95%CI) vs expected number of breast cancers diagnosed for each year
of follow-up, (b) cumulative observed (95%CI) vs expected number of breast cancers diagnosed; (c) observed (Nelson–Aalan, 95%CI) vs expected
cumulative hazards; (d) observed (Kaplan–Meier, 95%CI) vs expected (obtained via two methods) net risks; (e) Observed divided by Expected
cumulative hazard (95%CI); (f) Observed divided by expected net risk (obtained via two methods) with 95%CI only for the expected risk based on
baseline risk assessment.
year (or until the event or censoring if in that year) was in-
cluded as an offset term, and calibration coefficients were
estimated for (i) overall lack of calibration in the first year,
(ii) stability of calibration from year two onward (follow-
up year), and (iii) 10y risk categories from the model as
previously defined (<2%, 2 to <3%, 3 to < 5%, 5 to
< 8%, ≥ 8%; with 2–3% group as the reference category)
[14].
Results are shown in Table 2, taking the exponent of
the estimated model parameter to give a calibration co-
efficient where unity indicates ideal calibration. They
confirm the earlier analysis. The risk model over esti-
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TABLE 2
Calibration assessment: univariate and Poisson regression (adjusted for variables listed) calibration coefficient estimates with 95% Wald
confidence intervals
Term n O E O/E [univariate] O/E (95%CI) [adjusted]
Overall (intercept) 132,139 2699 2757 0.98 1.05 (0.94–1.16)
Follow-up time
Year 1 132,139 87 178 0.49 0.50 (0.40–0.63)
Year 2+ (time) 123,830 2612 2579 1.01 1.00 (0.99–1.01)
10y Risk group
<2% 53,436 641 548 1.12 1.17 (1.00–1.25)
2 to <3% 33,269 627 603 1.04 1
3 to <5% 29,477 779 784 0.99 0.96 (0.86–1.07)
5 to <8% 11,312 379 473 0.80 0.78 (0.68–0.88)
8%+ 4645 273 349 0.78 0.76 (0.66–0.88)
mated risk in the first year by a factor of two (calibra-
tion coefficient 0.50, 95%CI 0.40–0.63), which is due
to the expected short-term reduction in risk following a
negative screen. There was no loss in calibration subse-
quently (calibration 1.00, 95%CI 0.99–1.01). The high-
est risk category (10y risk ≥ 8%) exhibited evidence of
over-estimation of risk relative to the reference average-
risk category (calibration overall 0.80, 95%CI 0.69–0.92,
i.e., including the intercept), and likewise there was some
under-estimation in the lowest-risk group (overall test for
calibration across the five groups likelihood-ratio χ2 =
48.6, df = 4).
7. CONCLUSION
In this paper, we reviewed the statistical foundations of
a model to evaluate breast cancer risk at different follow-
up times. This model, and corresponding computer pro-
gram, synthesise findings from many scientific studies by
combining risk factors into a hybrid genetic segregation
and regression model. The model has been used to guide
entry criteria into prevention trials [23], and is recom-
mended by several organisations to guide preventive and
early detection strategies, including the American Can-
cer Society to help determine eligibility for supplemental
breast magnetic resonance imaging [57].
We developed new graphical methods for looking at
calibration over follow-up time that can be combined with
Poisson regression analysis. The impact of using the dif-
ferent methods to assess the calibration of cumulative ab-
solute risk was reviewed. Different methods to account
for competing risks when assessing risk model calibration
have been used. We note that, given the diversity of meth-
ods in use and potential impact on findings, it is important
when presenting calibration findings that a detailed de-
scription of the method for expected risk is also given [1].
There are opportunities to refine and improve the cur-
rent risk model. Other factors are known to affect the risk
of breast cancer, but most have some difficulties for in-
clusion in a relatively simple model. Using weight change
from age 20 or weight at a young age in addition to cur-
rent weight does appear to improve risk assessment to
some extent [37], but requires accurate recall of previous
weight. Alcohol consumption is a well documented risk
factor [35], but underestimation of consumption is well
known and it is not clear how best to allow for this. The
differing roles of weight in the pre- and postmenopausal
periods also needs further investigation [58]. Physical ac-
tivity and dietary factors are also known to affect risk
[50, 71], but identification of the key factors and simple
accurate measures of these currently present difficulties.
Levels of oestrogens and testosterone may also be im-
portant especially for postmenopausal women, but these
require a blood sample and are not routinely available
[72]. Ethnic differences in breast cancer risk are also well
documented—notably in the US lower risks in Hispan-
ics and Asians [8]. However, it is unclear as to how these
are related to differences in the known risk factors in the
model, so would not need model recalibration, or whether
there are intrinsic ethnic differences which require use of
a separate baseline hazard function, and possibly separate
risks for the known factors. Differences between recent
migrants and established individuals are also known to
exist and complicate any model adjustments [39]. Adding
breast density has substantially improved the model, and
might be extended by considering longitudinal measure-
ments of density and features in the mammogram other
than simply breast density, where more complex algo-
rithms may be able to extract more risk information [67].
The polygenic (SNP) risk score is steadily being improved
as more SNPs are added, but this is easily accommodated
as all that is required is the relative risk. A bigger chal-
lenge is to accurately account for interactions between
risk factors. Our model was developed by synthesizing
risks for individual factors from large overviews of many
studies, and large datasets which contain all the factors
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will be needed to fully explore interactions. These are not
currently available but are likely to be so soon, as the risk
factors used in our model are currently being collected in
several large cohorts of patients.
In conclusion, we are gradually moving towards an era
of precision medicine, where disease treatment, early de-
tection and prevention strategies will depend on risk as-
sessment. The accuracy of risk models will underpin this
approach.
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